Apricot Capital
VC Fund
Boston, United States
Apricot Capital is a seed stage investment firm based in Boston, MA and Toronto, Canada. Investments: awe.sm, Careport Health, Clypd, Crashlytics (acquired 2012), Habit Labs, Kinvey, Massive Damage, Momentfeed, MyTime, OnSwipe, Placester, Smart Lunches, TribeHR (acquired 2013), Peekaboo Mobile (acquired 2011)
- Total investments:
- 10
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries Apricot Capital invests in
Stages Apricot Capital invests in
Countries Apricot Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $1M–$10M
- Series A
- $1.1M–$3.2M
Investment Focus
Industry
- Health Care 4 (40%)
- Biotechnology 4 (40%)
- Advertising 3 (30%)
- Internet 2 (20%)
- Software 2 (20%)
Stage
- Seed 3 (30%)
- Series A 3 (30%)
- Angel 1 (10%)
- Series E 1 (10%)
- Funding Round 1 (10%)
Country
- United States 7 (70%)
- China 1 (10%)
- Malaysia 1 (10%)
- Cayman Islands 1 (10%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Peter Wernau
Co-Founder, Managing Partner
|
Co-Founder, Managing Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Fountain Medical Development Ltd., a contract research organization, provides ICH GCP compliant clinical research services for the multinational clients in China and the United States. It offers consulting, project management, regulatory affairs, clinical operations, central laboratory services, site management, biometrics, and clinical trialdesigns, as well as AE/SAE collection, review, assessment and reporting services, data and safety monitoring board handling, and signal detection services. The company is based in Beijing, China. | $150M / Series E / Jul 04, 2022 | ||
| Kind Kones is an all-natural vegan ice cream brand. The ice creams are vegan and free from dairy, egg, refined sugar, and other artificial additives with mostly gluten-free options. | $1.1M / Series A / Jan 31, 2022 | ||
D2M Biotherapeutics
|
D2M Biotherapeutics focuses on the development of novel immunotherapeutics. The company is a tumor immunological drug developer that aims to expand the potential of immunotherapy. | $10M / Seed / Aug 23, 2020 | |
| GenomiCare Biotechnology (Shanghai) Co., Ltd is a Chinese precision cancer medicine service company, providing personalized clinical precision medicine solutions and medical resources for Chinese cancer patients and doctors. | Series A / Dec 01, 2017 | ||
| Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeuticpeptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788. | $45M / Venture - Series Unknown / Aug 04, 2016 | ||
| Smart Lunches is an online ordering and delivery platform that enables parents to order school lunch for their children. They also provide a valuable enhanced service to the school, convenience, and nutritional security to the parents, and a good lunch to the students. It aims to make the midday meal simple and healthy. Smart Lunches was foundedin 2011 and is headquartered in Boston, Massachusetts, United States. | $4.4M / Jun 20, 2014 | ||
| Placester is an all-in-one business platform for real estate professionals with beautiful lead capturing websites, lead management, email marketing, marketing automation, analytics, free education and 24/7 support. Founded in 2011 by Matthew Barba, a former real estate agent, and Frederick Townes, a seasoned technologist, the Placesterplatform enables real estate professionals to grow their businesses online and via mobile through seamless MLS integration, natural language search and eye-catching visuals. In addition, Placester offers a wide range of apps and add-ons for high-impact email marketing, digital advertising campaigns, lead management and streamlining of everyday tasks. Currently serving two in five real estate professionals in the U.S., Placester is a proud technology partner to leading real estate brands across North America, and the sole website provider for the REALTOR Benefits® Program, the official member benefits program of the National Association of REALTORS®. To date, Placester has raised $100 million in funding, backed by New Enterprise Associates (NEA), Romulus Capital and Techstars. For more information, please visit placester.com. | $2.5M / Seed / Apr 29, 2013 | ||
| clypd is the advertising technology platform built exclusively for the television industry, empowering media owners with programmatic ad solutions. Founded in 2012, the company’s TV sales platform delivers workflow automation, data-enhanced decisioning, and provides media partners with tools to manage their sales efforts. Its innovations aroundprogrammatic television are opening doors for incremental digital budgets currently not available to the TV media owners. The clypd team is comprised of both TV and digital advertising experts, which uniquely positions the company to understand and meet the needs of the television industry while leveraging the best programmatic strategies from the digital world. | $3.2M / Series A / Mar 05, 2013 | ||
| awe.sm measures how social marketing leads to more signups, purchases, and other business goals that drive financial outcomes. Its customer base includes brands and developers in technology, media, and retail.The company currently markets two products:Using awe.sm’s marketer-facing product, a brand that markets on Twitter can log into areporting tool that reveals the specific business outcomes — for example, sales, registrations, or subscriptions — generated by each specific post. The tool also tracks how many people saw each tweet, re-shared it, marked it as a favorite, or replied to it; as well as how many clicks, pageviews and conversions the post generated. The tool additionally provides optimizations and insights, such as identifying important followers and recommending when to post in the future.awe.sm’s core technology also is available to software developers and websites as a suite of developer APIs. These tools enable programmatically creating tracking links; amassing custom metadata — for example, for which social network a link is being created, which customer or user created a link, or relevant keywords or product SKUs associated with the link; and retrieving click, pageview, conversion outcomes, and other statistics about each link or group of links. The APIs are used to power social features and applications, including marketing automation tools, social games, commerce, and customer rewards programs. | $1M / Seed / Dec 01, 2010 | ||
| Peekaboo Mobile provides a platform to local businesses looking to connect to consumers with location-targeted offers. Peekaboo says that it currently reaches over 50 million smartphone users through its Android and iPhone deal applications and partner network. | Angel / Oct 01, 2010 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Apricot Capital invest in?
Apricot Capital invests primarily in Health Care, Biotechnology and Advertising startups, most often at Seed and Series A stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Apricot Capital invest in?
Apricot Capital typically joins rounds of $1M–$10M at Seed and $1.1M–$3.2M at Series A. These are whole funding-round sizes, not Apricot Capital's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Apricot Capital took part in.
How do I contact Apricot Capital?
Public channels for Apricot Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Apricot Capital?
The team at Apricot Capital includes Peter Wernau (Co-Founder, Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
